Literature DB >> 18957489

Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis.

T Uhlig1, T K Kvien, T Pincus.   

Abstract

AIM: To examine the test-retest reliability of the rheumatoid arthritis (RA) core disease activity measures and derived composite indices.
METHODS: A total of 28 stable patients with RA had 2 complete assessments within 1 week, which included the 7 RA core disease activity measures and derived disease activity indices (28-joint Disease Activity Score (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), RA Disease Activity Index (RADAI) and Routine Assessment of Patient Index Data (RAPID3)). The intraclass correlations (ICC), the smallest detectable difference (SDD) and minimal detectable change as percentage of the maximum score (MDC%) were estimated as measures of test-retest reliability.
RESULTS: Correlations for the disease activity indices were high. SDDs (MDC%) to detect a true improvement or deterioration with 95% confidence were: DAS28 1.32 (14.4%), SDAI 8.26 (9.6%), CDAI 8.05 (10.6%), RAPID3 1.48 (14.8%) and RADAI 1.49 (14.9%). Thus, SDDs were rather high, and the MDC% values were of a similar magnitude of 10% to 15% for all seven core data set measures.
CONCLUSIONS: SDDs of the DAS28, SDAI and CDAI were close to limits to detect important improvement. Clinicians should be aware of measurement error. Nonetheless, RA core data set measures and indices obtained from a health professional, laboratory and patient self-report had similar reliability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18957489     DOI: 10.1136/ard.2008.097345

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  24 in total

1.  Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; Salvador Macías-Díaz; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Pamela Soto-Santillán; Beatriz Pérez-Romano; Erick A Jiménez-Herrera; Omar Guzmán-Ruiz; Alejandro Ruiz-Argüelles
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

2.  Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis.

Authors:  Michael M Ward; Isabel Castrejon; Martin J Bergman; Maria I Alba; Lori C Guthrie; Theodore Pincus
Journal:  J Rheumatol       Date:  2018-10-15       Impact factor: 4.666

3.  Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.

Authors:  J R Curtis; S Yang; L Chen; J E Pope; E C Keystone; B Haraoui; G Boire; J C Thorne; D Tin; C A Hitchon; C O Bingham; V P Bykerk
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

4.  Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies.

Authors:  Michaela Koehm; Matthew J McIntosh; Michael W Hofmann; Varghese Abraham; Cem Gabay; Ernest H Choy; Arthur Kavanaugh; Harald Burkhardt; Frank Behrens
Journal:  Rheumatol Int       Date:  2020-02-10       Impact factor: 2.631

5.  Test-retest reliability of the disease activity score 28 CRP (DAS28-CRP), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints.

Authors:  Cecilie Heegaard; Lene Dreyer; Charlotte Egsmose; Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

6.  Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria.

Authors:  Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2016-06-09       Impact factor: 2.980

7.  FRAX fracture risk in women with a recent fracture of the distal forearm: agreement between assessments with and without bone mineral density and impact of measurement side in the individual patient.

Authors:  Emilie Lund Egsmose; Mette Birkvig; Thora Buhl; Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2014-05-14       Impact factor: 2.980

8.  Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis.

Authors:  Lisanne Renskers; Ron J J C van Uden; Anita M P Huis; Sanne A A Rongen; Steven Teerenstra; Piet L C M van Riel
Journal:  Clin Rheumatol       Date:  2018-09-12       Impact factor: 2.980

9.  Reply.

Authors:  Jeffrey R Curtis; Sindhu R Johnson; Donald D Anthony; Reuben J Arasaratnam; Lindsey R Baden; Ellen M Gravallese; Anne R Bass; Cassandra Calabrese; Rafael Harpaz; Andrew Kroger; Rebecca E Sadun; Amy S Turner; Eleanor Anderson Williams; Ted R Mikuls
Journal:  Arthritis Rheumatol       Date:  2021-07-16       Impact factor: 15.483

10.  A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.

Authors:  Stanley Cohen; Alvin F Wells; Jeffrey R Curtis; Rajat Dhar; Theodore Mellors; Lixia Zhang; Johanna B Withers; Alex Jones; Susan D Ghiassian; Mengran Wang; Erin Connolly-Strong; Sarah Rapisardo; Zoran Gatalica; Dimitrios A Pappas; Joel M Kremer; Alif Saleh; Viatcheslav R Akmaev
Journal:  Rheumatol Ther       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.